Drug Pricing Regulator NPPA Revises Ceiling Prices Of 128 Medicines

Drug pricing regulator National Pharmaceutical Pricing Authority has revised prices of 128 drugs, including antibiotics and antiviral medications.

The formulations for which the ceiling price has been fixed include antibiotic injections of Amoxicillin and Clavulanic acid; Vancomycin, asthma medication Salbutamol, cancer drug Trastuzumab, brain tumour treatment drug Temozolomide, painkiller Ibuprofen and paracetamol which is used to treat pain and fever.

As per the notification, the ceiling price of one Amoxicillin capsule has been fixed at Rs 2.18; one tablet of Cetirizine at Rs 1.68; Amoxicillin and Clavulanic acid injection at Rs 90.38; Ibuprofen 400 mg tablet at Rs 1.07.

"All manufacturers of scheduled formulation, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and notified by the government, shall revise the prices of all such formulations downward not exceeding the ceiling price," the notification said.

The National Pharmaceutical Pricing Authority (NPPA) has also fixed the retail price of 12 scheduled formulations under Drugs (Prices Control) Order, 2013 (NLEM 2022). The retail price of one tablet of anti-diabetes combination drug Glimepiride, Voglibose & Metformin (extended release) has been fixed at Rs 13.83.

Similarly, retail price of one tablet of Paracetamol, Phenylephrine Hydrochloride, Diphenhydramine Hydrochloride and Caffeine has been fixed at Rs 2.76.

Set up in 1997, has been entrusted with the task of fixation/revision of prices of pharma products, enforcement of provisions of DPCO and monitoring of prices of controlled and decontrolled drugs.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

RECENT NEWS

Revoluts Australian Banking Licence Game Changer

Revolut has spent much of its life insisting that it is more than a bank. In Australia, it has now decided that becoming... Read more

The AI Bank Is Coming, But Who Controls The Risk?

Artificial intelligence is no longer something banks discuss as a distant possibility. It is already working behind the ... Read more

ClearBank UK Profit Leads To European Growth

ClearBank has spent much of the past decade building the technology and regulatory infrastructure needed to challenge so... Read more

Bank Of London Continues To Rebuild

ClearBank’s progress shows that modern clearing and banking infrastructure can become a sizeable and profitable busine... Read more

JPMorgan's Berlin Moment: Chase Takes On Europe

There is something quietly symbolic about JPMorgan Chase choosing Berlin as its gateway into continental Europe. In a fo... Read more

What Strategy's Bitcoin Sale Really Tells Us

There is a moment in every bull run when the narrative starts to fray. Not with a crash, not with a scandal, but with so... Read more